ArticleFrontiers in artificial intelligence2026
A multimodal, risk-stratified framework for AI-driven early risk prediction and personalised prevention in obesity.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a multifactorial chronic disease whose worldwide prevalence in adults has more than doubled since 1990, demanding a shift from reactive treatment towards early, personalised prevention. Artificial intelligence (AI) provides a methodological pathway for this shift by integrating heterogeneous, longitudinal evidence-genomic, metabolomic, electronic health record (EHR), wearable Internet-of-Things (IoT), behavioural, and social-environmental-and by translating that evidence into individualised, time-varying risk estimates. Yet the field is fragmented: most existing tools are unimodal, validated on narrow cohorts, opaque to clinicians, and disconnected from the workflows that would render their predictions actionable. In this Perspective we propose an explicit multimodal, risk-stratified framework that links five data layers to a continuous dynamic risk score R(t), defined as a weighted, time-varying aggregation of clinical, anthropometric, behavioural, psychosocial and pharmacological domains. R(t) drives an A/B/C tiering policy that allocates monitoring intensity and intervention modality proportional to risk, and feeds a metabolic-behavioural digital-twin loop in which counterfactual interventions are tested in silico before deployment. We argue that three technical commitments are non-negotiable for translation: (i) cross-modal fusion architectures that respect informative missingness, (ii) explainable, equity-audited risk scoring, and (iii) a five-stage validation pipeline anchored in TRIPOD-AI, decision-curve analysis and post-market drift surveillance. We discuss how this framework reframes long-standing concerns-black-box opacity, demographic bias, real-world fragility-as design constraints rather than afterthoughts, and outline an actionable research agenda for clinically deployable, equitable AI in obesity prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.